Back to Journals » OncoTargets and Therapy » Volume 10

Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study

Authors Gao L, Li SH, Tian YX, Zhu QQ, Chen G, Pang YY, Hu XH

Received 18 March 2017

Accepted for publication 9 May 2017

Published 20 July 2017 Volume 2017:10 Pages 3667—3683

DOI https://doi.org/10.2147/OTT.S137433

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 4

Editor who approved publication: Dr William Cho

Li Gao,1,* Sheng-Hua Li,2,* Yi-Xin Tian,1 Qing-Qing Zhu,1 Gang Chen,3 Yu-Yan Pang,3 Xiao-Hua Hu1

1Department of Medical Oncology, 2Department of Urology Surgery, 3Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

*These authors contributed equally to this work

Abstract: It has been discovered that miR-133a-3p acts as a tumor suppressor in bladder cancer (BC). Nevertheless, the function of miR-133a-3p in BC remains unclarified. Thus, we carried out this study to validate the expression of miR-133a-3p in BC and provide insights into the molecular mechanism underlying it. To assess the expression of miR-133a-3p in BC, we searched eligible studies from literature and Gene expression Omnibus (GEO) to perform a meta-analysis. We also plotted the summary receiver operating characteristic (SROC) curve to evaluate the diagnostic ability of miR-133a-3p in BC. Additionally, the potential target genes of miR-133a-3p were acquired from 14 online software programs and GEO database. Protein-protein interaction (PPI) network was created to identify the hub genes. Then, Gene Ontology (GO) functional annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were carried out to investigate the regulatory network of the target genes. From the meta-analysis, miR-133a-3p was remarkably downregulated in BC tissues compared with that in non-cancer tissues (standard mean difference =-3.84, 95% confidence interval =-6.99–0.29). Moreover, results from SROC suggested that miR-133a-3p exhibited the ability to diagnose BC (area under curve =0.8418). As for the bioinformatics study, 488 genes were chosen as the potential targets of miR-133a-3p in BC, among which 10 genes were defined as hub genes (all degrees >5). Further GO and KEGG pathway analysis indicated that the target genes of miR-133a-3p aggregated in specific biological process and pathways. In conclusion, miR-133a-3p possessed great diagnostic potential with its downregulation in BC, and miR-133a-3p might serve as a novel biomarker for BC.

Keywords:
bladder cancer, target genes, miR-133a-3p, meta-analysis, bioinformatics study
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report

Ma FC, Yu Q, Zeng ZM, He RQ, Mo CH, Zhong JC, Ma J, Feng ZB, Chen G, Hu XH

OncoTargets and Therapy 2017, 10:5237-5242

Published Date: 1 November 2017